S. 150 · 118th Congress · Health
Affordable Prescriptions for Patients Act of 2023
- IntroducedJan 30, 2023 Done
- CommitteeReported Mar 1, 2023 Done
- Senate floorPassed by unanimous consent · Jul 11, 2024 Done
- House floorDied Jan 3, 2025 Stopped here
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.
Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Congressional Research Service · summary of “Passed Senate” version · Jul 11, 2024
Who lobbies on it
31 organizations · 233 filings · Q1 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Chamber of Commerce of the U.s.a.
8 of 8 quarters
“H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 8070, National Defense Authorization Act for Fiscal Year 2025 S. 79, Interagency Patent Coordination and Improvement Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 150, Affordable Prescriptions for Patients Act of 2023…”
-
Pharmaceutical Research and Manufacturers of America
8 of 8 quarters
“H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents…”
-
Pharmaceutical Care Management Association (pcma)
8 of 8 quarters
“Pharmacy Benefit Manager Issues, S.150 - Affordable Prescriptions for Patients Act of 2023, H.R.10545 - American Relief Act, 2025, H.R.5378 - Lower Costs, More Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, S.2973 - Modernizing and Ensuring PBM Accountability Act”
28 more organizations, every filingPROUpgrade
Organizations that named S. 150 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
11 actions · newest first- Jul 15, 2024Held at the desk.
- Jul 15, 2024Received in the House.
- Jul 12, 2024Message on Senate action sent to the House.
- Jul 11, 2024Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Show all 11 actionsShow fewer
- Jul 11, 2024Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
- Jul 11, 2024Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
- Mar 1, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
- Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
- Feb 9, 2023Committee on the Judiciary. Ordered to be reported without amendment favorably.
- Jan 30, 2023Read twice and referred to the Committee on the Judiciary.
- Jan 30, 2023Introduced in Senate